Skip to main content

Advertisement

SpringerLink
Log in

Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus

Putting evidence into practice

  • Clinical Review
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

Purpose

To summarize current knowledge of interventions that should improve the care of patients with type II diabetes mellitus. Interventions lie within the realms of prevention, screening, and treatment, all of which are focused on office practice.

Methods

Review of the literature by a multidisciplinary team involved in the care of patients with diabetes, followed by synthesis of the literature into a clinical care guideline. Literature was identified through consultation with experts and a focused MEDLINE search.

Main Results

An algorithm-based guideline for screening and treatment of the complications of diabetes was developed. The emphasis is on prevention of atherosclerotic disease, and prevention, screening, and early treatment of microvascular disease. Implementation of these practices has the potential to significantly improve quality of life and increase life expectancy in patients with type II diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda. Md: National Institutes of Health; 1995.

    Google Scholar 

  2. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med. 1996;125:221–32.

    Google Scholar 

  3. The Diabetes Control and Complications Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409–15.

    Google Scholar 

  4. Krolewski AS, Czyczyk A, Janeczko D, Kopczynski J. Mortality from cardiovascular disease among diabetics. Diabetologa. 1977: 13:345–50.

    Article  CAS  Google Scholar 

  5. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123–31. Published erratum appears in Diabetologia. 1987;30:364.

    Google Scholar 

  6. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of diabetic retinopathy study findings. Ophthalmology. 1981;88(7):583–600. DRS Report Number 8.

    Google Scholar 

  7. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. Ophthalmology. 1991;98(suppl):766–85. ETDRS Report Number 9.

    Google Scholar 

  8. Brechner RJ, Cowie CC, Howie LJ, Herman WH, Will JC, Harris MI. Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA. 1993;270:1714–18.

    Article  PubMed  CAS  Google Scholar 

  9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, VI: retinal photocoagulation. Ophthalmology. 1987;94:747–53.

    PubMed  CAS  Google Scholar 

  10. Witkin SR, Klein R. Ophthalmologic care for persons with diabetes. JAMA. 1984;251:2534–7.

    Article  PubMed  CAS  Google Scholar 

  11. Harris M. Medical care for patients with diabetes: epidemiologic aspects. Ann Intern Med. 1996;24(1 pt 2):117–22.

    Google Scholar 

  12. Kannel W, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA. 1979;241:2035–8.

    Article  PubMed  CAS  Google Scholar 

  13. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984–1991. Am J Epidemiol. 1994;140:857–69.

    PubMed  CAS  Google Scholar 

  14. Ronnemaa T, Laakso M, Pyorala K, Kallio V, Puukka P. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb. 1991;11:80–90.

    PubMed  CAS  Google Scholar 

  15. Pyorala K, Uusitupa M, Laakso M, Siitonen B, Niskanen L, Ronnemaa T. Macrovascular complications in relation to hyperinsulinemia in non-insulin-dependent diabetes mellitus. Diabetes Metab. 1987;13:345–9.

    CAS  Google Scholar 

  16. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960–7.

    Article  PubMed  CAS  Google Scholar 

  17. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor. Diabetes Care. 1995;18:1299–1304.

    PubMed  CAS  Google Scholar 

  18. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175–84.

    Article  PubMed  CAS  Google Scholar 

  19. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl J Med. 1996;334:952–7.

    Article  Google Scholar 

  20. Abraira C, Colwell JA, Nuttall FQ. et al. Veterans Affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Diabetes Care. 1995; 18:1113–23.

    Article  PubMed  CAS  Google Scholar 

  21. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study, VIII: study design, progress, and performance. Diabetologia. 1991;34:877–90.

    Article  Google Scholar 

  22. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.

    Google Scholar 

  23. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study Report 14. JAMA. 1992;268(10):1292–300.

    Article  Google Scholar 

  24. Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians's Health Study. N Engl J Med. 1989;321:129–35.

    Article  Google Scholar 

  25. Hseuh WA, Anderson PW. Hypertension, the endothelial cell and the vascular complications of diabetes mellitus. Hypertension. 1992;20:253–63.

    Google Scholar 

  26. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 1982;285:685–8.

    Article  PubMed  CAS  Google Scholar 

  27. Fuller JH. Epidemiology of hypertension associated with diabetes mellitus. Hypertension. 1985;7(suppl II):IIxxx3–7.

    Google Scholar 

  28. Sowers JR, Ebstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension. 1995; 26(pt 1):869–79.

    PubMed  CAS  Google Scholar 

  29. National Center for Health Statistics. Plan and operation of the Hispanic Health and Nutrition Examination Survey. 1982–1984. In: Vital Health Stat 1. Washington, DC: Department of Health and Human Services; 1985: 19 DHHS publication PHS 85–1321.

    Google Scholar 

  30. National High Blood Pressure Education Program Working Group. Report on hypertension in diabetes. Hypertension. 1994; 23:145–58.

    Google Scholar 

  31. Langer RD. General population studies of the benefits and epidemiology of hypertension. The epidemiology of hypertension control in populations. Clin Exp Hypertens. 1995;7(7):1127–44.

    Article  Google Scholar 

  32. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97–104.

    Article  Google Scholar 

  33. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program, I: reduction in mortality in persons with high blood pressure, including mild hypertension. JAMA. 1979;242: 2562–71.

    Article  Google Scholar 

  34. Crub JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996; 276:1886–92.

    Article  Google Scholar 

  35. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154–83.

    Article  Google Scholar 

  36. Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ. 1989;298:227–30.

    Article  PubMed  CAS  Google Scholar 

  37. Dodson PM, Pacy PJ, Bal P, Kubicki AJ, Fletcher RF, Taylor KG. A controlled trial of a high fibre, low fat and low sodium diet for mild hypertension in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1984;27:522–6.

    Article  PubMed  CAS  Google Scholar 

  38. Savage S, Nagel NJ, Estacio RO, Lukken N, Schrier RW. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis. 1995;25:836–44.

    Article  PubMed  CAS  Google Scholar 

  39. Chuang LM, Jou TS, Wu HP, Tseng CH, Tai TY, Lin BJ. Effect of treatment of borderline hypertension on microalbuminuria in non-insulin-dependent diabetes mellitus. J Formos Med Assoc. 1991;90:531–5.

    PubMed  CAS  Google Scholar 

  40. Lebovitz HE, Weigmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM role of baseline albuminuria. Kidney Int. 1994;45(suppl 45):S150–5.

    CAS  Google Scholar 

  41. Hypertension in Diabetes Study III. Prospective study of therapy of hypertension in type 2 diabetic patients efficacy of ACE inhibition and β-blockade. Diabetes Med 1994;11:773–82.

    Article  Google Scholar 

  42. Neilson FS, Rossing P, Gall M, Skøtt P, Smidt UM, Parving HH. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1994; 43:1108–13.

    Article  Google Scholar 

  43. Lewis E, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.

    Article  PubMed  CAS  Google Scholar 

  44. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-tern stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577–81.

    PubMed  CAS  Google Scholar 

  45. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286–9.

    Article  Google Scholar 

  46. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an, angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793–5.

    Article  PubMed  CAS  Google Scholar 

  47. Ferrier C, Ferrari P, Weidman P, Keller U, Beretta-Piccoli C, Reisen WF. Antihypertensive therapy with Ca antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care. 1991;14:911–4.

    Article  PubMed  CAS  Google Scholar 

  48. Abbott K, Smith A, Bakris GL. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996;36:274–9.

    Google Scholar 

  49. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995;35:73–80.

    PubMed  CAS  Google Scholar 

  50. Fogari R, Žoppi A, Pasotti C, et al. Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function. J Hum Hypertens. 1995;9:131–5.

    PubMed  CAS  Google Scholar 

  51. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ. 1991;302:210–6.

    Article  Google Scholar 

  52. Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the Systolic Hypertension in the Elderly Program. Hypertension. 1993;21:335–43.

    Google Scholar 

  53. Warram JH, Laffel LM, Valsania P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med. 1991;151:1350–6.

    Article  PubMed  CAS  Google Scholar 

  54. Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low and conventional-dose thiazide diuretics on insulin action in hypertensive patients with NIDDM. Diabetologia. 1995; 38:853–9.

    Article  PubMed  CAS  Google Scholar 

  55. Olsoson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double blind randomized trials. Eur Heart J. 1992;13:28–32.

    Google Scholar 

  56. Gunderson T, Kuekshus JT. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care. 1983;6:285–90.

    Article  Google Scholar 

  57. Roberts WC. Recent studies on the effects of beta-blockers on blood lipid levels. Am Heart J. 1989;117:709–14.

    Article  PubMed  CAS  Google Scholar 

  58. Feher MD. Doxazosin therapy in, the treatment of diabetic hypertension. Am Heart J. 1991;121:1291–301.

    Article  Google Scholar 

  59. Bakris G, Barnhill BW, Sadler R. Treatment of arterial, hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992;41:912–9.

    Article  PubMed  CAS  Google Scholar 

  60. Schneider M, Lerch M, Papiri M, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose-chlortalidone treatment in hypertensive type 2 diabetics. J Hypertens. 1996;14:669–77.

    Article  Google Scholar 

  61. Dornhurst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet. 1985:1(8421):123–6

    Article  Google Scholar 

  62. Fontbonne A, Eschwege E, Cambien F. et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989:32:300–4.

    Article  PubMed  CAS  Google Scholar 

  63. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992:15:820–5.

    Article  PubMed  CAS  Google Scholar 

  64. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994:344:1383–9.

    Article  Google Scholar 

  65. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995:333:1301–7.

    Article  Google Scholar 

  66. Summary of the Second Report of the National Cholesterol Program (NCEP) Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993:269:3015–23.

    Google Scholar 

  67. Farrer M, Winocour PH, Evans K, et al. Simvastatin in non-insulin dependent diabetes mellitus: effect on serum lipids, lipoproteins and hemastatic measures. Diabetes Res Clin Pract. 1994: 23:111–9.

    Article  PubMed  CAS  Google Scholar 

  68. Sweany A, Shapiro D, Tate A, Goldberg R, Stein E. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin dependent diabetes mellitus. Clin Ther. 1995;17:186–203.

    Article  PubMed  CAS  Google Scholar 

  69. Garg A, Grundy S. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;26:723–6.

    Article  Google Scholar 

  70. Shen D, Fuh MM, Shieh S, Ida Chen Y, Reaven GM. Effect of gemfi-brozil treatment in sulfonylurea-treated patients with non insulin-dependent diabetes. J Clin Endocrinol Metab. 1991;73:503–10.

    Article  PubMed  CAS  Google Scholar 

  71. Huttunen JK, Heinonen OP, Manninen V, et al. The Helsinki Heart Study: an 8.5 year safety and mortality follow-up. J Intern Med. 1994;235:31–9.

    Article  PubMed  CAS  Google Scholar 

  72. Suarez L, Barrett-Conner E. Interaction between cigarette smoking and diabetes mellitus in the prediction of death attributed to cardiovascular disease. Am J Epidemiol. 1984;120:670–5.

    PubMed  CAS  Google Scholar 

  73. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–8.

    Article  Google Scholar 

  74. The Diabetes Control and Complications Trials Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–83.

    Article  Google Scholar 

  75. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care. 1978;1:168–88 (pt 1) and 252–63(pt 2).

    Google Scholar 

  76. Klein R, Klein BEK, Moss SE. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260(19):2864–71.

    Article  PubMed  CAS  Google Scholar 

  77. Klein R, Klein BEK, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124(1 pt 2):90–6.

    Google Scholar 

  78. Singer DE, Nathan DM, Fogel HA, Schachat AP. Screening for diabetic retinopathy. Ann Intern Med. 1992;116:660–71.

    PubMed  CAS  Google Scholar 

  79. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;10(6):356–60.

    Article  Google Scholar 

  80. Bennet PH, Haffner S, Kasiske BL, et al. Diabetic renal disease recommendations. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995;25:107–12.

    Article  Google Scholar 

  81. Delcourt C, Villatte-Cathelineau B, Vauzelle-Kervroedan F, Papoz L. Clinical correlates of advanced retinopathy in type II diabetic patients: implications for screening. J Clin Epidemiol. 1996;49(6): 679–85.

    Article  Google Scholar 

  82. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases: a meta-analysis. Ann Intern Med 1996;124:627–32.

    Google Scholar 

  83. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.

    Article  PubMed  CAS  Google Scholar 

  84. Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care. 1989;12:24–31.

    Article  PubMed  CAS  Google Scholar 

  85. Sonsenko JM, Kato M, Soto R, Bild DE. Comparison of quantitative sensory-threshold measures for their association with foot ulceration in diabetic patients. Diabetes Care. 1990;13:1057–61.

    Article  Google Scholar 

  86. Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying patients at risk for lower extremity amputation in a primary health care setting: a prospective evaluation of simple screening criteria. Diabetes Care. 1992;15:1386–9.

    Article  PubMed  CAS  Google Scholar 

  87. Litzelman D, Slemenda C, Langefield C, et al. Reduction in lower extremily clinical abnormalities in patients with non-insulin-dependent diabetes. Ann Intern Med. 1993;119:36–41.

    PubMed  CAS  Google Scholar 

  88. Uccioli L, Faglia E, Monticone G, et al. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care. 1995;10:1376–8.

    Article  Google Scholar 

  89. Sima AAF, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an ARI. N Engl J Med. 1988;319:548–55.

    Article  PubMed  CAS  Google Scholar 

  90. Greene D, Arezzo J, Brown M, and the Ženarestat Study Group. Dose-related effects of the aldose reductase inhibitor Ženarestat on nerve sorbitol levels nerve conduction velocity and nerve fiber density in human diabetic neuropathy. Diabetes. 1996;45:A9. Abstract.

    Google Scholar 

  91. Feldman EL, Stevens MJ, Greene DA. Treatment of diabetic neuropathy. In: Mazzaferri EL, Bar RS, eds. Advances in Endocrinology and Metabolism, Vol 5. St. Louis, Mo: Mosby Year Book Inc.: 1994:5:393–428.

    Google Scholar 

  92. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994;331:854–60.

    Article  PubMed  CAS  Google Scholar 

  93. Edmonds NE, Blundell MP, Morris ME, et al. Improved survival of the diabetic foot: the role of a specialized foot clinic. QJM. 1986;6:763–71.

    Google Scholar 

  94. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;4:1249–58.

    Google Scholar 

  95. McCance DR, Hanson RL, Charles M, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994;308:1323–8.

    PubMed  CAS  Google Scholar 

  96. Gabbay KH, Hasty K, Breslow JL, et al. Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus. J Clin Endocrinol Metab. 1977;44:859–64.

    Article  PubMed  CAS  Google Scholar 

  97. Bunn HF. Evaluation of glycosylated hemoglobin in diabetic patients. Diabetes. 1981;30:613–7.

    PubMed  CAS  Google Scholar 

  98. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 1997;20(suppl 1):S14–7.

    Google Scholar 

  99. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc. 1995;95:1009–17.

    Article  PubMed  CAS  Google Scholar 

  100. American Diabetes Association. National standards for diabetes self-management education programs. Diabetes Care. 1995;18:141–4.

    Google Scholar 

  101. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 1987;147:1749–53.

    Article  PubMed  CAS  Google Scholar 

  102. Reaven GM. Beneficial effect of moderate weight loss in older patients with non-insulin-dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc. 1985;33:93–5.

    PubMed  CAS  Google Scholar 

  103. Watts NB, Spanheimer RG, DiGirolamo M, et al. Prediction of glucose diabetes mellitus. Arch Intern Med. 1990;150:803–6.

    Article  PubMed  CAS  Google Scholar 

  104. Franz MJ, Horton ED, Sr, Bantle JP, et al. Nutrition principles for the management of diabetes and related complications. Diabetes Care. 1994;17:490–518.

    PubMed  CAS  Google Scholar 

  105. Jenkins DJA, Ocana A, Jenkins A, et al. Metabolic advantages of spreading the nutrient load: effects of increased meal frequency in non-insulin-dependent diabetes. Am J Clin Nutr. 1992;55:461–7.

    PubMed  CAS  Google Scholar 

  106. Bertelsen J, Christiansen C, Thomsen C, et al. Effect of meal frequency on blood glucose, insulin and free fatty acids in NIDDM subjects. Diabetes Care. 1993;16:3–7.

    Article  Google Scholar 

  107. Palvou K, Krey NS, Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr. 1989;49:1115–23.

    Google Scholar 

  108. Wing RR. Behavioral treatment of obesity: its application to type II diabetes. Diabetes Care. 1993;16:193–9.

    Article  PubMed  CAS  Google Scholar 

  109. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231–45.

    Article  PubMed  CAS  Google Scholar 

  110. Lebovitz HE. Sulfonylurea drugs. In: Lebovitz HE. ed. Therapy for Diabetes and Related Disorders. 2nd ed. Alexandria, Va: American Diabetes Association; 1995:1160–23.

    Google Scholar 

  111. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes millitus. N Engl J Med. 1995;333:541–9.

    Article  PubMed  CAS  Google Scholar 

  112. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–9.

    Article  Google Scholar 

  113. Stumvoll M, Nurjhan N, Periello G, Dailery G, Derich JE. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:550–5.

    Article  PubMed  CAS  Google Scholar 

  114. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med. 1994;1221:928–35.

    Google Scholar 

  115. Lebovitz HE. A new oral therapy for diabetes management: alphagucosidase inhibition with acarbose. Clin Diabetes. Nov/Dec 1995:99–103.

    Google Scholar 

  116. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661–9.

    Article  Google Scholar 

  117. Kumar S, Boulton AJM, Beck-Nielson H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 1996;39:701–9.

    Article  Google Scholar 

  118. Soneru IL, Agrawal L, Murphy J, Lawrence AM, Abraira C. Comparison of morning and bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care. 1993;16:896–901.

    Article  PubMed  CAS  Google Scholar 

  119. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Insulin regimens in non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426–33.

    Article  PubMed  CAS  Google Scholar 

  120. Mills JL, Simpson JL, Driscoll SG, et al. Incidence of spontaneous abortion among normal women and women with insulin dependent diabetes whose pregnancies are identified within 21 days of conception. Diabetes in Early Pregnancy Study. N Engl J Med. 1988;319:1617–23.

    Article  PubMed  CAS  Google Scholar 

  121. Greene M, Hare JW, Cloherty JP, et al. First trimester HbA1c and the risk for major malformation and spontaneous abortion. Teratology. 1989;39:225–31.

    Article  PubMed  CAS  Google Scholar 

  122. Fuhrmann K, Reiher H, Semmler K, Fischer F, Fischer M, Glockner E. Prevention of congenital malformations in infants of insulin-dependent diabetic mothers. Diabetes Care. 1983;6:219–23.

    Article  PubMed  CAS  Google Scholar 

  123. Fuhrmann K, Reiher H, Semmler K, Glockner E. The effect of intensified conventional insulin therapy before and during pregnancy on the manlformation rate in offspring of diabetic mothers. Exp Clin Endocrinol. 1984;83:173–7.

    Article  PubMed  CAS  Google Scholar 

  124. Goldman JA, Dickerd D, Feldberg D. Pregnancy outcome in patients with insulin-dependent diabetes mellitus with pre-conceptual diabetic control: a comparative study. Am J Obstet Gynecol 1986;155:193–7.

    Google Scholar 

  125. Mills JL, Knopp RH, Simpson JL, et al. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med. 1988;318:671–6.

    Article  PubMed  CAS  Google Scholar 

  126. Steel JM, Jonstone FD, Hepburn DA, Smith A. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ. 1990;301:1070–4.

    Article  PubMed  CAS  Google Scholar 

  127. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic L, Main EK, Zigrang WD. Preconception care of diabetes: glycemic control prevents congenital anomalies. JAMA. 1991;265:731–6.

    Article  PubMed  CAS  Google Scholar 

  128. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol. 1996;174:(4):1343–53.

  129. Janz NK, Herman WH, Becker MP, et al. Diabetes and pregnancy: factors associated with seeking pre-conception care. Diabetes Care. 1995;18:157–65.

    Article  PubMed  CAS  Google Scholar 

  130. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner RE. Preconception care of diabetes, congenital malformations, and spontaneous abortions: a technical review. Diabetes Care. 1996;19:514–41.

    Google Scholar 

  131. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommentations for use. Am J Med. 1994;96:451–6.

    Article  PubMed  CAS  Google Scholar 

  132. Brown SA. Effects of educational interventions and outcomes in diabetic adults: a meta-analysis revisited. Patient Educ Couns. 1990;16:189–215.

    Article  PubMed  CAS  Google Scholar 

  133. Brown SA. Studies of educational interventions in diabetes care: a meta-analysis of findings. Nurs Res. 1988;37:223–30.

    PubMed  CAS  Google Scholar 

  134. Clement S. Diabetes self-management education: a technical review. Diabetes Care. 1995;18:1204–14.

    PubMed  CAS  Google Scholar 

  135. Funnell MM, Haas LB. National standards for diabetes self-management education programs: a technical review. Diabetes Care. 1995;18:100–16.

    Article  PubMed  CAS  Google Scholar 

  136. Goodall TA, Halford WK. Self-management of diabetes mellitus: a critical review. Health Psychol. 1991;10:1–8.

    Article  PubMed  CAS  Google Scholar 

  137. Gruesser M, Bott U, Ellermann P, Kronsbein P, Joergens V. Evaluation of a structured treatment and teaching program for non-insulin treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care. 1993;16:1268–75.

    Article  PubMed  CAS  Google Scholar 

  138. Padgett D, Mumford E, Hynes M, Carter R. Meta-analysis of the effects of educational and psychosocial interventions on management of diabetes mellitus. J Clin Epidemiol. 1988;41:1007–30.

    Article  PubMed  CAS  Google Scholar 

  139. Rubin RR, Peyrot M. Psychosocial problems and interventions in diabetes: a review of the literature. Diabetes Care. 1992;15:1640–57.

    Article  PubMed  CAS  Google Scholar 

  140. Nicolucci A, Cavaliere D, Scorpiglione N, et al. A comprehensive assessment of the avoidability of long-term complications of diabetes. Diabetes Care. 1996;19:927–33.

    Article  Google Scholar 

  141. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care. 1990;13:513–21.

    Article  PubMed  CAS  Google Scholar 

  142. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc. 1995;95:1009–17.

    Article  PubMed  CAS  Google Scholar 

  143. Raz I, Soskolne V, Stein P. Influence of small-group education sessions on glucose homeostasis in NIDDM. Diabetes Care. 1990;13:513–21.

    Article  Google Scholar 

  144. Muhlhauser I, Berger J. Diabetes education and insulin therapy. When will they ever learn? J Intern Med. 1993;233:321–6.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General Internal Medicine, University of Michigan Medical Center, 300 N. Ingalls, Rm. NI4A20, 48109-0474, Ann Arbor, MI

    Sandeep Vijan MD & Connie J. Standiford MD

  2. Division of Endocrinology and Metabolism, University of Michigan Medical Center, 300 N. Ingalls Rm. NI4A20, 48109-0474, Ann Arbor, MI

    William H. Herman MD, MPH

  3. Department of Internal Medicine: Department of Family Practice, University of Michigan Medical Center, 300 N. Ingalls Rm. NI4A20, 48109-0474, Ann Arbor, MI

    Deryth L. Stevens MD

  4. Diabetes Research and Training Center, University of Michigan Medical Center, 300 N. Ingalls Rm. NI4A20, 48109-0474, Ann Arbor, MI

    Martha M. Funnell MS, RN

Authors
  1. Sandeep Vijan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deryth L. Stevens MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William H. Herman MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martha M. Funnell MS, RN
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Connie J. Standiford MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vijan, S., Stevens, D.L., Herman, W.H. et al. Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. J GEN INTERN MED 12, 567–580 (1997). https://doi.org/10.1046/j.1525-1497.1997.07111.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.1997.07111.x

Key words

Search

Navigation